- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE Acquires Breast Ultrasound Developer U-Systems
GE Healthcare axquires U-Systems Inc., developer of the Automated Breast Ultrasound, a system used as a supplement to mammography for asymptomatic women with dense breasts and no prior interventions.
GE Healthcare announced last week the acquisition of U-Systems Inc., developer of a breakthrough ultrasound system approved for breast cancer screening.
U-Systems’ somo•v® Automated Breast Ultrasound (ABUS) was approved by the FDA in September as an adjunct to mammography for asymptomatic women with dense breasts and no prior breast interventions. The companies did not disclose the financial terms of the acquisition.
“The combination of U-Systems, Inc. and GE Healthcare uniquely positions GE to offer U.S. healthcare providers and their patients the most comprehensive portfolio of breast care innovations on the market - from screening to diagnosis to monitoring,” Tom Gentile, president and CEO of GE Healthcare Systems, said in a statement.
Studies have shown that women with dense breast tissue are at a greater risk of breast cancer compared with those with little or no dense tissue.
"The worldwide resources of GE Healthcare will allow us to expand and accelerate our efforts to commercialize the recently FDA-Approved somo•v® ABUS,” Ron Ho, U-Systems president and CEO, said in a statement. “With our combined resources and capabilities, we have the opportunity to make a significant impact on breast cancer detection and patient outcomes around the world.”
MRI or Ultrasound for Evaluating Pelvic Endometriosis?: Seven Takeaways from a New Literature Review
September 13th 2024While noting the strength of MRI for complete staging of disease and ultrasound’s ability to provide local disease characterization, the authors of a new literature review suggest the two modalities offer comparable results for diagnosing pelvic endometriosis.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Controlled Contrast Delivery Method for Ultrasound Imaging of Fallopian Tubes
September 9th 2024Facilitating natural contrast delivery through an intrauterine catheter, FemChec can be utilized for ultrasound assessment of fallopian tubes and may provide diagnostic confirmation for an emerging non-surgical option for permanent birth control.
FDA Clears Emerging Cardiovascular Point-of-Care Ultrasound Platform
August 22nd 2024Combining four CAD modules for valvular pathologies with a variety of automated measurements, the AI-enabled AISAP Cardio ultrasound system reportedly facilitates up to a 90 percent accuracy rate in detecting common cardiac conditions.
Predicting DCIS Upgrade to Invasive Breast Cancer: Can Contrast-Enhanced Ultrasound Have an Impact?
August 21st 2024Adding two key findings from contrast-enhanced ultrasound to a predictive model of mammography, conventional ultrasound and clinicopathological findings led to a 86.1 percent AUROC for predicting the upgrading of ductal carcinoma in situ to invasive breast cancer, according to new research.
